New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:35 EDTSWIR, NTGR, EMC, VMW, VLO, DHI, KERX, HES, LLY, PFE, FOn The Fly: Closing Wrap
Stocks on Wall Street were mixed as the Dow closed only 200 or so points away from a high it has not reached since October 2007. A less-than-stellar consumer confidence reading for January stalled the advance early in the session, but the averages all rebounded and closed at or near their best levels of the day, though the Nasdaq was unable to hold in positive ground... ECONOMIC EVENTS: In the U.S., the November S&P/Case-Shiller 20-city Home-Prices Index was up a seasonally adjusted 0.6% from the prior month, versus expectations for a 0.7% increase. On a year-over-year basis, the 20-city index rose 5.5%, which was nearly in-line with consensus. The Consumer Confidence reading for January fell to 58.6, versus expectations for a smaller decline to 64.0... COMPANY NEWS: Ford (F) reported quarterly results that beat expectations on both the top and bottom lines. However, concerns over Europe, where the company said it expects to lose about $2B in 2013, sent shares down 64c, or 4.64%, to $13.14... Pharma giants Pfizer (PFE) and Eli Lilly (LLY) both reported earnings that beat consensus estimates before the market opened and both rallied. Dow-member Pfizer led that index with a 3.2%, or 86c, advance to $27.70, while Lilly gained $1.68, or 3.19%, to $54.32... MAJOR MOVERS: Higher for the second straight day were shares of Hess (HES), up $5.63, or 9.01%, to $68.11 after gaining over 6% yesterday, and Keryx Biopharmaceuticals (KERX), up $2.30, or 38.01%, to $8.36 today after rising over 76% yesterday. Also higher after earnings reports were DR Horton (DHI), which gained $2.51, or 11.78%, to $23.82, and Valero (VLO), which added $4.96, or 12.78%, to $43.77. Among the noteworthy losers was VMware (VMW), down $21.18, or 21.54%, to $77.14 after its guidance disappointed the Street and the stock was downgraded by numerous firms. EMC (EMC), which holds a majority ownership stake in VMware and also reported last night, also lost $1.02, or 4.05%, to $24.18. Also lower were shares of NetGear (NTGR), down $4.45, or 10.9%, to $36.38 after agreeing to acquire Sierra Wireless's (SWIR) AirCard business assets for $138M in cash. Sierra Wireless (SWIR) advanced $1.69, or 18.45%, to $10.85 after the news... INDICES: The Dow was up 72.49, or 0.52%, to 13,954.42; the Nasdaq was down 0.64, or 0.02%, to 3,153.66; and the S&P 500 was up 7.66, or 0.51%, to 1,507.84.
News For F;PFE;LLY;HES;KERX;DHI;VLO;VMW;EMC;NTGR;SWIR From The Last 14 Days
Check below for free stories on F;PFE;LLY;HES;KERX;DHI;VLO;VMW;EMC;NTGR;SWIR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 19, 2014
08:09 EDTEMC, VMWVMware updates executive responsibilities
Subscribe for More Information
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
13:01 EDTFFord, Chevrolet launching incentives earlier than usual, Autmotive News says
Subscribe for More Information
11:41 EDTLLY, PFECubist rises after report sparks takeover interest speculation
Subscribe for More Information
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTPFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
07:37 EDTFReport says Russia may bar car imports if new sanctions enacted, Reuters says
Subscribe for More Information
August 15, 2014
18:25 EDTFFord announces recall of Focus, Escape due to wiring issue, Reuters says
Subscribe for More Information
06:28 EDTFFord issues recall due to potentially faulty halfshaft
Ford is recalling certain model year 2012-2014 Ford Edge and Lincoln MKX vehicles manufactured September 2, 2010, to November 30, 2013; 2013-2014 Ford Taurus and Lincoln MKS vehicles manufactured August 25, 2011, to November 30, 2013; and 2013-2014 Ford Flex and Lincoln MKT vehicles manufactured September 12, 2011, to November 30, 2013. In the affected vehicles, the halfshaft retention circlip may not have been properly installed, and as a result, the halfshaft may move outward and disengage from the linkshaft while driving and without prior warning. If the halfshaft and linkshaft become disengaged while driving, power will no longer be transmitted to the wheels, increasing the risk of a vehicle crash. Additionally, if the parking brake is not applied before exiting the vehicle, the vehicle may roll away despite the transmission being placed in "park'," increasing the risk of injury to exiting occupants and bystanders. Ford will notify owners, and dealers will inspect the vehicles to make sure that the halfshaft is properly retained. If it is not, dealers will replace the linkshaft and also replace the halfshaft if it shows evidence of spline damage, free of charge. The recall is expected to begin by August 29. Reference Link
August 14, 2014
17:41 EDTHESPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
17:16 EDTHESPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:05 EDTPFEPfizer says FDA accepted for review BLA for bivalent recombinant LP2086
Pfizer announced that the FDA has accepted for review the Biologics License Application,BLA, for bivalent recombinant LP2086, the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipated Prescription Drug User Fee Act, PDUFA, action date of February 14, 2015. “Pfizer has closely collaborated with the FDA since 2008 to develop our meningococcal B vaccine candidate with the intent to help prevent this devastating disease,” said Dr. Emilio Emini, senior vice president of Vaccine Research and Development for Pfizer. “Both the acceptance of Pfizer’s Biologics License Application today, and its Priority Review designation, are significant regulatory milestones that underscore the importance of our efforts to expedite the approval and subsequent availability of our meningococcal B vaccine for U.S. adolescents.”
11:45 EDTEMCNetApp rises after earnings beat, Needham upgrade
Shares of storage systems provider NetApp (NTAP) are advancing after the company posted better than expected first quarter results and received positive analyst commentary. WHAT'S NEW: Last night, NetApp reported Q1 adjusted earnings per share of 60c and revenue of $1.49B, beating analysts' consensus estimates of 57c and $1.47B, respectively. Q1 adjusted gross margin was 64.3%. WHAT'S NOTABLE: NetApp forecast second quarter adjusted EPS of 66c-71c and revenue of $1.49B-$1.59B, compared to consensus of 69c and $1.53B, respectively. For fiscal 2015, the company sees EPS growth just under 10% and revenue growth in the mid-single digits. FY15 adjusted gross margin is seen at 63%-64%. On NetApp's Q1 conference call, management said it was seeing a rebound in enterprise spending in the U.S. ANALYST REACTION: This morning, analyst commentary was overwhelmingly positive. Needham upgraded NetApp to Buy from Hold following its strong Q1 report, citing better enterprise spending. Their price target was $49. Two firms, Piper Jaffray and Brean Capital, raised their respective price targets on NetApp and Pacific Crest said NetApp is "'undervalued and underappreciated," noting that the company's Q1 results included 13% earnings growth year-over-year. PRICE ACTION: In late morning trading, NetApp rose $1.47, or 3.7%, to $40.77 on heavy trading volume. Despite today's advance, the stock is down approximately 4% over the past 12 months. OTHERS TO WATCH: Other companies in the storage space include: EMC (EMC), Dot Hill Systems (HILL) and Nimble Storage (NMBL).
11:36 EDTEMCEMC executive say 'Virtual Isilon' coming, IT Wire reports
EMC's Isilon storage product has proved popular in Australia with customers that need large amounts of storage and EMC CTO John Roese told a customer event in Melbourne this month that "Virtual Isilon" is coming this year, reported IT Wire. Reference Link
10:05 EDTF, KERXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:24 EDTHESLibya to restart exports from Es Sider oil port, WSJ reports
Libya will resume exports from Es Sider, its largest oil port, next week following a one-year disruption, sources tell the Wall Street Journal. Es Sider's preliminary loading plans involve six 60,000 barrel tankers drawing on oil stored at the terminal, split between state-owned National Oil Co, Hess (HES), ConocoPhillips (COP) and Marathon Oil (MRO). Reference Link
05:35 EDTKERXKeryx initiated with a Market Perform at FBR Capital
Target $16.
August 13, 2014
16:16 EDTFFord initiated with a Neutral at Credit Suisse
Target $18.15.
08:16 EDTFFord upgraded at Stifel
As previously reported, Stifel upgraded Ford to Buy from Hold. Thea analyst upgraded shares based on better than expected year-to-date trends, commentary that indicate the F-150 launch is on track, higher than expected Q2 North American margins, and a portfolio refresh cycle. Price target is $22.
06:59 EDTFFord upgraded to Buy from Hold at Stifel
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use